Log in
updated 5:20 AM PDT, May 25, 2016

Pfizer results beat estimates

WSJ: The pharmaceutical giant posted earnings of $2.91 billion, or 45 cents per share.

WSJ: The pharmaceutical giant posted earnings of $2.91 billion, or 45 cents per share.

Revenue decreased 1.5% to $12.77 billion, hurt by foreign currency changes and the expiration of the co-promotion term for Enbrel, a psoriasis and rheumatoid arthritis drug.

Analysts had projected per-share earnings of 57 cents and revenue of $12.47 billion.

Research and development spending rose 13% to $1.71 billion.

Read more here.

Last modified onMonday, 19 October 2015 11:43

Leave a comment

Make sure you enter all the required information, indicated by an asterisk (*). HTML code is not allowed.

Get our original content straight to your inbox.
Enter your email below to sign up for our daily enewsletter